6-hydroxy-4-(trifluoromethyl)quinolin-2(1H)-one | 328956-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-hydroxy-4-(trifluoromethyl)quinolin-2(1H)-one
• 英文别名: 6-hydroxy-4-(trifluoromethyl)-1H-quinolin-2-one
• CAS: 328956-14-5
• 化学式: C₁₀H₆F₃NO₂
• 分子量: 229.158
• InChiKey: AAPBOSHGPMKCKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-hydroxy-4-(trifluoromethyl)quinolin-2(1H)-one 、 乙酸酐 在 溶剂黄146 作用下， 反应 6.0h， 以90%的产率得到2-oxo-4-(trifluoromethyl)-1,2-dihydroquinolin-6-yl acetate
  参考文献：
  名称：

  Substrate specificity of acetoxy derivatives of coumarins and quinolones towards Calreticulin mediated transacetylation: Investigations on antiplatelet function

  摘要：

  Calreticulin transacetylase (CRTAase) is known to catalyze the transfer of acetyl group from polyphenolic acetates (PA) to certain receptor proteins (RP), thus modulating their activity. Herein, we studied for the first time the substrate specificity of CRTAase towards N-acetylamino derivatives of coumarins and quinolones. This study is endowed with antiplatelet action by virtue of causing CRTAase catalyzed activation of platelet Nitric Oxide Synthase (NOS) by way of acetylation leading to the inhibition of ADP/Arachidonic acid (AA)-dependent platelet aggregation. Among all the N-acetylamino/acetoxy coumarins and quinolones screened, 7-N-acetylamino-4-methylcoumarin (7-AAMC, 17) was found to be the superior substrate to platelet CRTAase and emerged as the most promising antiplatelet agent both in vitro and in vivo. Further it caused the inhibition of cyclooxygenase-1 (Cox-1) resulting in the down regulation of thromboxane A2 (TxA2), modulation of tissue factor and the inhibition of platelet aggregation. It was also found effective in the inhibition of LPS induced pro-thrombotic conditions. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.016
• 作为产物：
  描述：

  6-methoxy-4-(trifluoromethyl)quinolin-2(1H)-one 在 氢溴酸 、 溶剂黄146 作用下， 反应 72.0h， 以70%的产率得到6-hydroxy-4-(trifluoromethyl)quinolin-2(1H)-one
  参考文献：
  名称：

  Substrate specificity of acetoxy derivatives of coumarins and quinolones towards Calreticulin mediated transacetylation: Investigations on antiplatelet function

  摘要：

  Calreticulin transacetylase (CRTAase) is known to catalyze the transfer of acetyl group from polyphenolic acetates (PA) to certain receptor proteins (RP), thus modulating their activity. Herein, we studied for the first time the substrate specificity of CRTAase towards N-acetylamino derivatives of coumarins and quinolones. This study is endowed with antiplatelet action by virtue of causing CRTAase catalyzed activation of platelet Nitric Oxide Synthase (NOS) by way of acetylation leading to the inhibition of ADP/Arachidonic acid (AA)-dependent platelet aggregation. Among all the N-acetylamino/acetoxy coumarins and quinolones screened, 7-N-acetylamino-4-methylcoumarin (7-AAMC, 17) was found to be the superior substrate to platelet CRTAase and emerged as the most promising antiplatelet agent both in vitro and in vivo. Further it caused the inhibition of cyclooxygenase-1 (Cox-1) resulting in the down regulation of thromboxane A2 (TxA2), modulation of tissue factor and the inhibition of platelet aggregation. It was also found effective in the inhibition of LPS induced pro-thrombotic conditions. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.016

文献信息

• Bicyclic androgen and progesterone receptor modulator compounds and methods
  申请人：Zhi Lin

  公开号：US20050288350A1

  公开（公告）日：2005-12-29

  The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis.

  本发明涉及化合物、制药组合物和调节由AR和PR介导的过程的方法。更具体地，本发明涉及非甾体化合物和组合物，它们是高亲和力、高特异性的AR和PR激动剂、部分激动剂（即部分激活剂和/或组织特异性激活剂）和拮抗剂。还提供了制备这些化合物和制药组合物的方法，以及在它们的合成中使用的关键中间体。
• BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS
  申请人：LIGAND PHARMACEUTICALS INCORPORATED

  公开号：EP1212303A2

  公开（公告）日：2002-06-12
• JP2003508387A
  申请人：——

  公开号：JP2003508387A

  公开（公告）日：2003-03-04
• US6566372B1
  申请人：——

  公开号：US6566372B1

  公开（公告）日：2003-05-20
• US6964973B2
  申请人：——

  公开号：US6964973B2

  公开（公告）日：2005-11-15